Pharmaceutical major Eli Lilly has suffered a further clinical setback with the failure of teplizumab, its investigational type I diabetes biologic.

A data monitoring committee found that the drug had failed to meet its primary efficacy endpoint when it completed a planned analysis of safety and efficacy data.

Eli Lilly and MacroGenics have since decided to suspend two other ongoing clinical trials of the medication, and have confirmed they will consider the options available to them.